Ex vivo manipulation of hematopoietic stem cells for transplantation: The potential role of amifostine

M. Balzarotti, S. Grisanti, K. Granzow, A. Saladini, A. Sala, A. Nozza, A. Molteni, F. Passamonti, C. Carlo-Stella, A. Santoro, S. Siena

Research output: Contribution to journalArticle

Abstract

High-dose chemotherapy with autologous stem cell transplantation is an increasingly used procedure in oncohematologic diseases and represents a promising strategy in selected patients with solid tumors. In autologous stem cell transplantation, the risk of reinfusion of clonogenic tumor cells is a remarkable biologic obstacle that can be at least partly overcome by ex viva graft purging to reduce residual tumor. Mafosfamide and 4- hydroxyperoxycyclophosphamide, active metabolites of cyclophosphamide, are the most widely used pharmacologic agents for ex vivo bone marrow purging. However, in addition to killing tumor cells, they are toxic to normal bone marrow as measured by reduced colony-forming unit granulocyte-macrophage (CFU-GM). Thus, the therapeutic index of these alkylating agents is narrow, and parameters for dose selection must include toxicity to normal bone marrow progenitor cells that can delay bone marrow engraftment and increase risk of infections, bleeding complications, hospitalization, and the need for a costly transplantation procedure. Amifostine (WR-2771, Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) selectively protects human CFU-GM progenitor cells from the cytotoxicities of active metabolites of cyclophosphamide without altering its cytotoxic effect on malignant cells. This has been demonstrated both in preclinical and clinical studies in patients with breast cancer, malignant lymphomas, and acute leukemia. Amifostine use during the ex vivo procedure significantly shortened the time to bone marrow engraftment with decreased incidence of infections and need for red blood cell transfusions.

Original languageEnglish
Pages (from-to)66-71
Number of pages6
JournalSeminars in Oncology
Volume26
Issue number2 SUPPL. 7
Publication statusPublished - 1999

Fingerprint

Amifostine
Hematopoietic Stem Cell Transplantation
Granulocyte-Macrophage Progenitor Cells
Bone Marrow
Stem Cell Transplantation
Cyclophosphamide
Bone Marrow Purging
Stem Cells
Erythrocyte Transfusion
Neoplasms
Poisons
Alkylating Agents
Residual Neoplasm
Infection
Bone Marrow Cells
Lymphoma
Leukemia
Hospitalization
Transplantation
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Balzarotti, M., Grisanti, S., Granzow, K., Saladini, A., Sala, A., Nozza, A., ... Siena, S. (1999). Ex vivo manipulation of hematopoietic stem cells for transplantation: The potential role of amifostine. Seminars in Oncology, 26(2 SUPPL. 7), 66-71.

Ex vivo manipulation of hematopoietic stem cells for transplantation : The potential role of amifostine. / Balzarotti, M.; Grisanti, S.; Granzow, K.; Saladini, A.; Sala, A.; Nozza, A.; Molteni, A.; Passamonti, F.; Carlo-Stella, C.; Santoro, A.; Siena, S.

In: Seminars in Oncology, Vol. 26, No. 2 SUPPL. 7, 1999, p. 66-71.

Research output: Contribution to journalArticle

Balzarotti, M, Grisanti, S, Granzow, K, Saladini, A, Sala, A, Nozza, A, Molteni, A, Passamonti, F, Carlo-Stella, C, Santoro, A & Siena, S 1999, 'Ex vivo manipulation of hematopoietic stem cells for transplantation: The potential role of amifostine', Seminars in Oncology, vol. 26, no. 2 SUPPL. 7, pp. 66-71.
Balzarotti, M. ; Grisanti, S. ; Granzow, K. ; Saladini, A. ; Sala, A. ; Nozza, A. ; Molteni, A. ; Passamonti, F. ; Carlo-Stella, C. ; Santoro, A. ; Siena, S. / Ex vivo manipulation of hematopoietic stem cells for transplantation : The potential role of amifostine. In: Seminars in Oncology. 1999 ; Vol. 26, No. 2 SUPPL. 7. pp. 66-71.
@article{a6aae58d1c7643c882f61e585a6d1d06,
title = "Ex vivo manipulation of hematopoietic stem cells for transplantation: The potential role of amifostine",
abstract = "High-dose chemotherapy with autologous stem cell transplantation is an increasingly used procedure in oncohematologic diseases and represents a promising strategy in selected patients with solid tumors. In autologous stem cell transplantation, the risk of reinfusion of clonogenic tumor cells is a remarkable biologic obstacle that can be at least partly overcome by ex viva graft purging to reduce residual tumor. Mafosfamide and 4- hydroxyperoxycyclophosphamide, active metabolites of cyclophosphamide, are the most widely used pharmacologic agents for ex vivo bone marrow purging. However, in addition to killing tumor cells, they are toxic to normal bone marrow as measured by reduced colony-forming unit granulocyte-macrophage (CFU-GM). Thus, the therapeutic index of these alkylating agents is narrow, and parameters for dose selection must include toxicity to normal bone marrow progenitor cells that can delay bone marrow engraftment and increase risk of infections, bleeding complications, hospitalization, and the need for a costly transplantation procedure. Amifostine (WR-2771, Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) selectively protects human CFU-GM progenitor cells from the cytotoxicities of active metabolites of cyclophosphamide without altering its cytotoxic effect on malignant cells. This has been demonstrated both in preclinical and clinical studies in patients with breast cancer, malignant lymphomas, and acute leukemia. Amifostine use during the ex vivo procedure significantly shortened the time to bone marrow engraftment with decreased incidence of infections and need for red blood cell transfusions.",
author = "M. Balzarotti and S. Grisanti and K. Granzow and A. Saladini and A. Sala and A. Nozza and A. Molteni and F. Passamonti and C. Carlo-Stella and A. Santoro and S. Siena",
year = "1999",
language = "English",
volume = "26",
pages = "66--71",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 7",

}

TY - JOUR

T1 - Ex vivo manipulation of hematopoietic stem cells for transplantation

T2 - The potential role of amifostine

AU - Balzarotti, M.

AU - Grisanti, S.

AU - Granzow, K.

AU - Saladini, A.

AU - Sala, A.

AU - Nozza, A.

AU - Molteni, A.

AU - Passamonti, F.

AU - Carlo-Stella, C.

AU - Santoro, A.

AU - Siena, S.

PY - 1999

Y1 - 1999

N2 - High-dose chemotherapy with autologous stem cell transplantation is an increasingly used procedure in oncohematologic diseases and represents a promising strategy in selected patients with solid tumors. In autologous stem cell transplantation, the risk of reinfusion of clonogenic tumor cells is a remarkable biologic obstacle that can be at least partly overcome by ex viva graft purging to reduce residual tumor. Mafosfamide and 4- hydroxyperoxycyclophosphamide, active metabolites of cyclophosphamide, are the most widely used pharmacologic agents for ex vivo bone marrow purging. However, in addition to killing tumor cells, they are toxic to normal bone marrow as measured by reduced colony-forming unit granulocyte-macrophage (CFU-GM). Thus, the therapeutic index of these alkylating agents is narrow, and parameters for dose selection must include toxicity to normal bone marrow progenitor cells that can delay bone marrow engraftment and increase risk of infections, bleeding complications, hospitalization, and the need for a costly transplantation procedure. Amifostine (WR-2771, Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) selectively protects human CFU-GM progenitor cells from the cytotoxicities of active metabolites of cyclophosphamide without altering its cytotoxic effect on malignant cells. This has been demonstrated both in preclinical and clinical studies in patients with breast cancer, malignant lymphomas, and acute leukemia. Amifostine use during the ex vivo procedure significantly shortened the time to bone marrow engraftment with decreased incidence of infections and need for red blood cell transfusions.

AB - High-dose chemotherapy with autologous stem cell transplantation is an increasingly used procedure in oncohematologic diseases and represents a promising strategy in selected patients with solid tumors. In autologous stem cell transplantation, the risk of reinfusion of clonogenic tumor cells is a remarkable biologic obstacle that can be at least partly overcome by ex viva graft purging to reduce residual tumor. Mafosfamide and 4- hydroxyperoxycyclophosphamide, active metabolites of cyclophosphamide, are the most widely used pharmacologic agents for ex vivo bone marrow purging. However, in addition to killing tumor cells, they are toxic to normal bone marrow as measured by reduced colony-forming unit granulocyte-macrophage (CFU-GM). Thus, the therapeutic index of these alkylating agents is narrow, and parameters for dose selection must include toxicity to normal bone marrow progenitor cells that can delay bone marrow engraftment and increase risk of infections, bleeding complications, hospitalization, and the need for a costly transplantation procedure. Amifostine (WR-2771, Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) selectively protects human CFU-GM progenitor cells from the cytotoxicities of active metabolites of cyclophosphamide without altering its cytotoxic effect on malignant cells. This has been demonstrated both in preclinical and clinical studies in patients with breast cancer, malignant lymphomas, and acute leukemia. Amifostine use during the ex vivo procedure significantly shortened the time to bone marrow engraftment with decreased incidence of infections and need for red blood cell transfusions.

UR - http://www.scopus.com/inward/record.url?scp=0033057234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033057234&partnerID=8YFLogxK

M3 - Article

C2 - 10348263

AN - SCOPUS:0033057234

VL - 26

SP - 66

EP - 71

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 7

ER -